Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Payables (2023 - 2025)

Bioharvest Sciences has reported Payables over the past 3 years, most recently at $2.8 million for Q4 2025.

  • For Q4 2025, Payables fell 62.64% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, down 62.64%, while the annual FY2025 figure was $2.8 million, 62.64% down from the prior year.
  • Payables was $2.8 million for Q4 2025 at Bioharvest Sciences, down from $7.2 million in the prior quarter.
  • Across five years, Payables topped out at $11.2 million in Q1 2025 and bottomed at $1.8 million in Q4 2023.
  • The 3-year median for Payables is $7.2 million (2025), against an average of $6.1 million.
  • Year-over-year, Payables skyrocketed 317.89% in 2024 and then plummeted 62.64% in 2025.
  • Over 3 years, Payables stood at $1.8 million in 2023, then skyrocketed by 317.89% to $7.4 million in 2024, then plummeted by 62.64% to $2.8 million in 2025.
  • The last three reported values for Payables were $2.8 million (Q4 2025), $7.2 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.